Guest guest Posted November 19, 2010 Report Share Posted November 19, 2010 The Food and Drug Administration said Friday that Xanodyne Pharmaceuticals has agreed to halt marketing of Darvon and the related brand Darvocet, which have been subject to safety concerns for decades. The FDA has also called on generic drugmakers to stop marketing low-cost drugs containing the active ingredient in Darvon, called propoxyphene. Julio G Romero Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.